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Marrow adipose tissue (MAT) is an endocrine organ with the potential to influence skel-
etal remodeling and hematopoiesis. Pathologic MAT expansion has been studied in the 
context of severe metabolic challenge, including caloric restriction, high fat diet feeding, 
and leptin deficiency. However, the rapid change in peripheral fat and glucose metab-
olism associated with these models impedes our ability to examine which metabolic 
parameters precede or coincide with MAT expansion. Microfibril-associated glycopro-
tein-1 (MAGP1) is a matricellular protein that influences cellular processes by tethering 
signaling molecules to extracellular matrix structures. MAGP1-deficient (Mfap2−/−) mice 
display a progressive excess adiposity phenotype, which precedes insulin resistance 
and occurs without changes in caloric intake or ambulation. Mfap2−/− mice were, there-
fore, used as a model to associate parameters of metabolic disease, bone remodeling, 
and hematopoiesis with MAT expansion. Marrow adiposity was normal in Mfap2−/− mice 
until 6 months of age; however, by 10 months, marrow fat volume had increased five-
fold relative to wild-type control at the same age. Increased gonadal fat pad mass and 
hyperglycemia were detectable in Mfap2−/− mice by 2 months, but peaked by 6 months. 
The development of insulin resistance coincided with MAT expansion. Longitudinal 
characterization of bone mass demonstrated a disconnection in MAT volume and bone 
volume. Specifically, Mfap2−/− mice had reduced trabecular bone volume by 2 months, 
but this phenotype did not progress with age or MAT expansion. Interestingly, MAT 
expansion in the 10-month-old Mfap2−/− mice was associated with modest alterations in 
basal hematopoiesis, including a shift from granulopoiesis to B lymphopoiesis. Together, 
these findings indicate MAT expansion is coincident with insulin resistance, but not 
excess peripheral adiposity or hyperglycemia in Mfap2−/− mice; and substantial MAT 
accumulation does not necessitate a proportional decrease in either bone mass or bone 
marrow cellularity.
Keywords: marrow adipose tissue, obesity, insulin resistance, bone remodeling, hematopoiesis, microfibril-
associated glycoprotein-1
Abbreviations: ECM, extracellular matrix; MAT, marrow adipose tissue; MAGP1, microfibril-associated glycoprotein-1.
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inTrODUcTiOn
Adipose tissue exists in multiple variations, the most extensively 
studied being: brown, white, and beige. Brown adipocytes 
specialize in utilizing energy to produce heat (thermogenesis), 
white adipocytes are energy-storing reservoirs, and beige 
adipocytes principally store lipids but can be stimulated to 
transdifferentiate into a “brown-like” state (1). Less studied is a 
fourth lipid storing depot, located within the skeleton, marrow 
adipose tissue (MAT). These skeleton-associated adipocytes 
arise from a unique progenitor (2) and occupy approximately 
70% of the marrow space within adult human bones (3). 
There is an evidence that MAT adipocytes exist in two forms: 
regulated marrow adipocytes (rMATs) that respond in size 
and number to physiological challenge, and the constitutive 
marrow adipocytes (cMATs) that persist despite challenge (4). 
Marrow adipocytes are not inert space-filling cells. Rather, 
the ability to produce leptin and adiponectin classifies them 
as an endocrine organ (5, 6). These cells also release fatty 
acids via lipolysis, suggesting that they may fuel local cellular 
processes (7).
Pathologic MAT expansion, as a consequence of metabolic 
dysfunction, has been studied in several contexts, including 
caloric restriction, high fat diet feeding, and leptin deficiency 
(6, 8–10). Unfortunately, the rapid change in peripheral fat and 
glucose metabolism associated with these models impedes our 
ability to determine which metabolic parameters precede or 
coincide with MAT expansion. The objective of this study was 
to correlate parameters of metabolic disease, bone remodeling, 
and hematopoiesis with MAT volume. Thus, we chose a model 
of progressive metabolic dysfunction – mice lacking the extracel-
lular matrix (ECM) protein microfibril-associated glycoprotein-1 
(MAGP1).
The ECM is a milieu of structural proteins, proteoglycans, 
and adhesive glycoproteins (11). MAGPs are a non-structural 
component of the ECM. The biology of this family has been 
recently reviewed (12). Briefly, MAGP1 (Mfap2) is broadly 
expressed, including both adipose tissue and bone (13, 14), 
and typically associates with fibrillin-rich microfibrils. 
MAGP1 may also interact with collagen-VI fibers (15). 
Characterization of MAGP1-deficient mice (Mfap2−/−) sug-
gests that MAGP1 does not contribute to the mechanical 
integrity of its associated ECM fibers (16). Rather, MAGP1 
functions as a gatekeeper of signal transduction. A significant 
body of evidence has demonstrated that MAGP1 interacts 
with ligands of the transforming growth factor beta (TGFβ) 
superfamily; sequestering them in the ECM (13, 14, 16, 17). 
In mice, MAGP1 deficiency (Mfap2−/−) results in adipocyte 
hypertrophy in peripheral white adipose tissue (WAT), dia-
betes, and reduced bone mass (13, 14). These phenotypes are 
progressive, developing with age.
Using the Mfap2−/− model, we demonstrate that MAT expan-
sion occurs concurrent with insulin resistance, not excessive 
peripheral adiposity or hyperglycemia. Bone loss in the MAGP1-
deficient mice occurs without corresponding increases in MAT. 
Furthermore, a fivefold increase in MAT in the proximal tibia 
does not negatively affect bone marrow (BM) cellularity.
MaTerials anD MeThODs
animals and Diet
All animals were C57BL/6 background males, housed in a 
pathogen-free animal facility and fed standard chow ad libitum. 
MAGP1-deficient mice were generated using C57BL/6-derived 
ES cells [Mfap2tm1a(KOMP)Wtsi] purchased from KOMP Repository 
(Davis, CA, USA). ES cells were injected into blastocyst from 
C57BL/6 donors and transferred into pseudopregnant C57BL/6 
females. Offspring were maintained on the Jackson Laboratories 
C57BL/6J strain. These mice are a newly derived line and are 
therefore different from the Mfap2−/− mice used in previous stud-
ies (13, 14, 16, 17). All animals were treated in accordance with 
animal protocols approved by the Animal Studies Committee at 
Washington University.
Tissue collection
Tissues were harvested at 2, 6, and 10 months. Mouse fur was 
sprayed with 70% EtOH, then gonadal white adipose tissue 
(gWAT), and tibias were collected. Tissues were cleaned thor-
oughly of all contaminants (hair, connective tissue, etc.), then 
frozen or stored in 10% neutral buffered formalin.
insulin Tolerance Test
For insulin tolerance tests (ITTs), mice were fasted for 6 h and 
then given an injection of 0.75 U/kg Humulin-R insulin (Lilly, 
Indianapolis, IN, USA). Insulin was delivered by intraperitoneal 
injection, and tail blood glucose concentration was measured 
using Contour strips and meters (Bayer, Whippany, NJ, USA) at 
the indicated intervals.
Osmium staining and Micro-computed 
Tomography
Micro-computed tomography (μCT) was completed on tibias 
from 2-, 6-, and 10-month-old mice. Bones were fixed in 10% 
neutral buffered formalin and then embedded in 2% agarose gel. 
Tibias were scanned at 20 μm voxel resolution using a Scanco μCT 
40 (Scanco Medical AG, Zurich, Switzerland) calibrated using a 
hydroxyapatite phantom. Measurements of both trabecular and 
cortical bones were made based on reported guidelines (18). For 
trabecular bone, 50 slices below the growth plate were contoured 
to exclude the cortical bone, allowing trabecular bone volume/
tissue volume (BV/TV) and bone mineral density (BMD) to be 
determined. For cortical bone, 20 slices – 2 mm proximal to the 
tibia–fibula junction were analyzed to determine cortical tissue 
mineral density (TMD). A threshold of 175 for trabecular bone 
and 260 for cortical bone (on a 0–1000 scale) was maintained. 
Note: two 10-month-old Mfap2−/− bones were excluded from 
study due to suspected fracture.
Tibias were then decalcified in 14% EDTA for 3  weeks. 
Demineralized bones were incubated in a solution containing 
1% osmium and 2.5% potassium dichromate for 48  h at room 
temperature. After thorough washing (water), tibias were embed-
ded in 1% agarose gel. Osmium stained bones were then scanned 
as above, using a Scanco μCT 40, but at 10 μm voxel resolution. 
Analysis was performed in the same region as the trabecular 
FigUre 1 | MaT expansion in Mfap2−/− mice. (a) Micro-computed tomography (μCT) visualization of osmium stained lipid within the decalcified proximal tibia. 
(B,c) Region analyzed for osmium volume (OV) was 1 mm distal to the growth plate. OV/TV is osmium volume divided by the marrow cavity volume in the same 
region. Mean ± SEM; Sample sizes for WT and Mfap2−/− mice, respectively: 2 months: n = 8, 8; 6 months: n = 6, 8; and 10 months: n = 8, 6. Statistical significance 
at each time point and within groups (WT or Mfap2−/−) over time was determined by two-way ANOVA with Holm–Sidak’s correction for multiple comparisons 
(*p ≤ 0.05, a = significant relative to 2 months of same genotype, and b = significant relative to 6 months of same genotype). Scale bar is 100 μm. Note: two 
10-month-old Mfap2−/− bones were excluded from study due to suspected fracture.
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bone (1,000 μm distal to the growth plate, 100 slices), using a 
threshold of 350 (on a 0–1000 scale). Osmium volume (OV) is 
quantification of the total OV within the region of interest. OV/
TV is division of the OV by the volume of the marrow cavity 
within the same region.
Flow cytometry
Blood, spleen, and BM (one each of pelvis bone, femur, and 
tibia) were harvested from Jackson Laboratories c57BL/6J 
WT and Mfap2−/− mice using standard techniques. Single cell 
suspensions were made, and red blood cells were lysed. Blood 
cells were counted using a Hemavet. BM and spleen cells were 
counted using a Cellometer. Ten million cells were stained and 
washed in FACS buffer (PBS, 1% BSA, 0.1% sodium aziade, 
and 2 μm EDTA). For monocyte, macrophage, and neutrophil 
analyses, cells from each tissue were stained with Brilliant 
Violet 421-conjugated F4/80 (BM8), peridinin chlorophyll 
protein complex (PerCP)-Cy5.5-conjugated MHC Class II 
(M5/114.15.2), phycoerythrin (PE)-Cy7-conjugated CD11c 
(N418), allophycocyanin (APC)-conjugated CD19 (1D3), 
APC-conjugated CD45R/B220 (RA3-6B2), APC-eFluor780-
conjugated Ly-6G (Gr1, RB6-8C5), and PE-conjugated CD115 
(AFS98). Two million live events were collected in the live gate 
and analyzed via FlowJo. Gating strategies can be found in 
Figure S1 in Supplementary Material.
statistical analysis
Statistical comparisons were performed using Graphpad 
Prism® (GraphPad Software, Inc., La Jolla, CA, USA). In 
Figures  1–3, with the exception of panel 2D, comparisons 
between wild-type (WT) and Mfap2−/− mice at each time point 
and over time within groups (WT or Mfap2−/−) were performed 
using a regular two-way ANOVA with Holm–Sidak correction 
for multiple comparisons. For the ITTs in panel 2D, repeated 
measures two-way ANOVA with Sidak’s correction was used. 
In Figures 4 and 5, results were compared with a two-tailed 
t-test. Comparisons with a P-value ≤0.05 were considered 
statistically significant.
FigUre 2 | characterization of metabolic disorder in Mfap2−/−mice. (a) Gonadal white adipose tissue (WAT) was harvested at 2 months (n = 10, 8), 6 months 
(n = 6, 8), and 10 months (n = 8, 8). (B) Total body weight at 2 months (n = 10, 8), 6 months (n = 7, 9), and 10 months (n = 8, 8). (c) Fasted (6 h) blood glucose 
concentration at 2 months (n = 10, 8), 6 months (n = 6, 8), and 10 months (n = 8, 8). (D) Insulin sensitivity results at 2 months (n = 10, 8), 6 months (n = 5, 8), and 
10 months (n = 8, 8). Blood glucose data were normalized to time point 0 (before insulin injection). Mean ± SEM; statistical significance in (a–c) at each time point 
and within groups (WT or Mfap2−/−) over time was determined by two-way ANOVA with Holm–Sidak’s correction for multiple comparisons. Statistical significance in 
(D) was determined by repeated-measured two-way ANOVA with Sidak’s correction (*p ≤ 0.05, a = significant relative to 2 months of same genotype, and 
b = significant relative to 6 months of same genotype). Sample sizes shown above are for WT and Mfap2−/− mice, respectively.
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resUlTs
Pathologic MaT expansion in  
Mfap2−/− Mice
To compare parameters of metabolic disease with MAT expan-
sion, a longitudinal study was performed in MAGP1-deficient 
(Mfap2−/−) mice that are susceptible to metabolic syndrome. 
Marrow adiposity was determined by μCT imaging of osmium 
stained lipid within the proximal tibia (Figure 1A). Quantification 
of total marrow lipid OV and OV normalized to total marrow cav-
ity volume (OV/TV) is shown in Figures 1B,C. Marrow adiposity 
was found to be indistinguishable in either young (2 months) or 
adult (6 months) Mfap2−/− mice, relative to WT mice. However, 
aged 10-month-old Mfap2−/− mice displayed a fivefold increase 
in marrow lipid (OV and OV/TV) relative to WT animals. WT 
C57BL/6 mice have only a modest, statistically insignificant, 
increase (54%) in MAT between 6 and 10 months.
characterization of Metabolic Dysfunction 
in Mfap2−/− Mice
Previously, we demonstrated that MAGP1 deficiency results in 
excess adiposity and reduced bone mass (13, 14, 16). Consistent 
with previous results, 2-month-old Mfap2−/− mice had only a 
modest 15% increase in white fat (as measured by gonadal fat 
pad mass, Figure 2A). However, by 6 months, Mfap2−/− mice had 
a 2.7-fold increase in fat mass, relative to WT mice. Extending 
our study to 10  months of age, we found that the differential 
in fat mass stabilizes, indicated by a 1.8-fold increase Mfap2−/− 
gonadal fat pad mass relative to WT mice. Total body weight 
reinforced this finding (Figure 2B). Mfap2−/− body weight was 
insignificantly increased at 2  months, but a significant (17%) 
increase in Mfap2−/− weight was found at 6  months. Similar 
to the fat mass measurement, the weight differential between 
WT and Mfap2−/− mice stabilized, remaining increased by 17% 
relative to baseline, at 10 months. Six-hour fasting blood glucose 
was significantly elevated in Mfap2−/− mice by 2 months (12%, 
Figure 2C). By 6 months, fasted blood glucose was 63% higher 
in Mfap2−/− mice relative to WT mice. However, by 10 months, 
there was only a 35% increase in Mfap2−/− blood glucose 
relative to WT. To characterize metabolic function, ITTs were 
performed on WT and Mfap2−/− mice at all ages (Figure 2D). 
In contrast to fat mass, body weight, and fasting blood glucose, 
insulin resistance did not reach statistical significance until 
the Mfap2−/− mice were 10-month old. Thus, Mfap2−/− mice 
FigUre 3 | skeletal changes in Mfap2−/− mice. Tibias were harvested at 2, 6, and 10 months. Micro-comupted tomography was used to determine the ratio of 
bone volume to total volume (BV/TV) and bone mineral density (BMD/TMD). (a–c) For trabecular bone, 1 mm distal to the growth plate was analyzed. (D) For 
cortical bone, tissue mineral density (TMD) was determined by contouring 400 μm located 2 mm proximal to the tibia–fibula junction. Sample size for WT and 
Mfap2−/− mice, respectively, are 2 months n = 8, 8; 6 months n = 6, 8; and 10 months n = 8, 6. Mean ± SEM; statistical significance at each time point and within 
groups (WT or Mfap2−/−) over time was determined by two-way ANOVA with Holm–Sidak’s correction for multiple comparisons (*p ≤ 0.05, a = significant relative to 
2 months of same genotype, and b = significant relative to 6 months of same genotype). Scale bar is 100 μm. Note: two 10-month-old Mfap2−/− bones were 
excluded from study due to suspected fracture.
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are severely hyperglycemic by 6 months in age, but not insulin 
resistant until 10 months.
relationship between MaT expansion and 
Bone Mass
Tibial bone morphology was assessed by μCT prior to osmium 
staining for MAT quantification (Figure  3A). Trabecular bone 
analysis was performed using the same region of interest analyzed 
for MAT (Figures 3B,C). Reduced trabecular bone volume (BV/
TV) and BMD were detectable in Mfap2−/− mice by 2 months. 
Aging of WT mice from 6 to 10  months was associated with 
statistically significant reductions in trabecular bone volume 
(−32%, Figure  3B) and mineral density (−19%, Figure  3C), 
but not a statistically significant increase in MAT (Figure 1C). 
During this time, Mfap2−/− mice had a 22% reduction in BV/
FigUre 4 | MaT expansion and hematopoiesis. To address the consequence of pathologic MAT expansion on hematopoiesis, the cellularity of the (a) bone 
marrow, (B) spleen, and (c) blood [white blood cells (WBCs)] were measured at 10 months. Sample size for WT and Mfap2−/− mice, respectively, are n = 8, 8 (a,B) 
or n = 8, 7 (c). Mean ± SEM; Student’s t-test was done for single comparison (*p ≤ 0.05 and ***p ≤ 0.001).
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TV (Figure 3B), but a 5.2-fold increase in MAT volume (OV/
TV, Figure  1C). Cortical bone density was maintained during 
aging and unchanged by MAT accumulation (Figure  3D). In 
fact, cortical BMD was highest at 10  months in both WT and 
Mfap2−/− mice. Additional μCT indices of bone structure can be 
found in Tables S1 and S2 in Supplementary Material.
MaT expansion and hematopoiesis
To address the impact of pathologic MAT expansion on hemat-
opoietic function, we measured the cellularity of the BM and 
spleen as well as the number of circulating white blood cells 
(WBCs) at 10 months of age. BM cellularity was not significantly 
reduced in Mfap2−/− mice, despite the fivefold increase in MAT 
(Figure  4A). However, spleen cellularity was slightly elevated 
and WBC count was decreased in Mfap2−/− mice (Figures 4B,C). 
To further investigate these findings, flow cytometry was used 
to assess hematopoietic lineage distribution. Within the BM of 
Mfap2−/− mice, there was a modest increase in macrophages, 
myeloid-derived dendritic cells (MDCs), and B-cells (+61, 
+78, and +18%, respectively) and a corresponding decrease in 
neutrophils relative to WT mice (−13%) (Figure  5A). In the 
spleen, there was a significant increase in MDCs (+250%) and 
decrease in neutrophils (−72%), with a trend to increased B-cells 
(Figure  5B). Finally, in the blood, we observed an increase in 
monocytes (+216%) and a modest decrease in B-cells (−15%) in 
Mfap2−/− mice (Figure 5C).
DiscUssiOn
Once viewed as inert, space-filling structures, BM adipocytes are 
now recognized as metabolically active cells with the potential 
to influence bone remodeling and hematopoiesis. The relation-
ship between MAT volume and peripheral fat mass has been 
addressed previously (9, 10). In rodents, weight gain resulting 
from HFD feeding is associated with significant MAT expansion. 
However, extreme peripheral fat loss due to caloric restriction also 
correlates with increased marrow adiposity (6). The rapid change 
in adiposity impedes our understanding of whether changes in 
peripheral adipose tissue lipid storage shift lipids to the marrow, 
or if metabolic changes such as insulin resistance contribute to 
MAT expansion. To address this question, we performed a lon-
gitudinal study of mice predisposed to excess, age-associated fat 
accumulation without dietary intervention.
Microfibril-associated glycoprotein-1 is a matricellular 
protein that associates with ECM structures but does not con-
tribute to their biophysical properties. Instead, MAGP1 affords 
fibrillar structures the capacity to regulate signal transduction 
by tethering growth factors to the ECM [reviewed in Ref. (12)]. 
MAGP1 is expressed in adipose tissue. MAGP1 deficiency in 
mice (Mfap2−/−) causes adipocyte hypertrophy in peripheral 
WAT, which contributes to obesity and then insulin resistance 
(13). MAGP1 is also highly expressed by osteoblasts in the bone. 
Loss of MAGP1 in vivo leads to increased osteoclast number and 
reduced bone mass (14). In this study, MAT expansion did not 
occur coincident with bone loss or excess peripheral adiposity in 
Mfap2−/− mice; osteopenia was detectable by 2 months and excess 
adiposity by 6 months in Mfap2−/− mice whereas pathologic MAT 
expansion was not detectable until 10 months of age. This suggests 
that MAGP1 deficiency in bone is sufficient to cause abnormal 
bone remodeling but is unlikely to be mediating the changes in 
MAT. Instead, MAT expansion coincided with insulin resistance 
in Mfap2−/− mice. Our findings are of importance because they 
address three confounding factors of MAT biology: the mecha-
nisms that drive MAT expansion, the relationship between MAT 
expansion and bone loss, and whether MAT is detrimental to 
hematopoiesis.
The coincidence of MAT expansion with insulin resistance 
suggests that insulin may limit MAT adipocyte size or number. 
Insulin signaling in marrow adipocytes has not been reported, 
thus, we cannot comment on insulin’s direct action on lipid 
storage or adipogenesis in these specialized cells. However, the 
pathophysiology of insulin resistance could induce a second-
ary complication (e.g., hyperlipidemia) that drives subsequent 
7Walji et al. MAT Expansion and Metabolic Disease
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FigUre 5 | neutrophil, macrophage, myeloid-derived dendritic cell, monocyte, and B cell frequency within the (a) bone marrow, (B) spleen, and (c) 
blood at 10 months. Neutrophils: B220−, Gr1+. Macrophage: B220−, Gr1−, MHCII+, F4/80+, and CD11c−. Dendritic cell: B220−, Gr1−, MHCII+, F4/80−, and 
CD11c+. Monocyte: B220−, Gr1−, and F4/80+. Sample sizes for WT and Mfap2−/− mice, respectively, are n = 8 and 8. Mean ± SEM; Student’s t-test was done for 
single comparison (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001).
MAT expansion. Insulin is a potent inhibitor of lipolysis, the 
breakdown of triglyceride stores, in traditional white adipocytes. 
Insulin resistance is therefore associated with elevated circulating 
free fatty acids (FFA) and excess energy storage in atypical sites 
(e.g., muscle and liver) (19). It is possible that marrow adipocytes 
respond to elevated FFA associated with insulin resistance by 
storing them as triglycerides. Rodent models of type 1 diabetes 
(T1DM) also display significant MAT accumulation (20–22), 
8Walji et al. MAT Expansion and Metabolic Disease
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providing a second example of perturbed insulin signaling asso-
ciating with hyperlipidemia and MAT expansion.
The relationship between marrow adiposity and bone mass is 
highly debated. Published reports have shown that MAT expan-
sion can coincide with increased, reduced, or unchanged bone 
volume (9, 10, 23–27).
Substantial in vitro evidence demonstrates that adipocytes and 
osteoblasts arise from the same mesenchymal progenitor. If true, 
maturation of mesenchymal stem cells through the adipocyte line-
age should be at the expense of the osteoblast lineage. However, 
in vivo evidence is conflicting. Specifically, lineage tracing of mar-
row adipocytes has demonstrated that the osteoblasts are derived 
from a Gremlin-1 positive mesenchymal progenitor cell, but these 
Gremlin-1 positive cells do not differentiate into adipocytes (28). 
This would allow osteoblast cell numbers to exist independent of 
marrow adipocyte number. The marrow cavity is also a relatively 
defined space, and it would, therefore, seem that expansion of MAT 
must occur at the expense of something else, such as bone. Our 
study supports a disconnection between MAT volume and bone 
volume. When WT and Mfap2−/− mice age from 6 to 10 months, 
there is an increase in MAT and decrease in BV/TV. However, 
loss of trabecular BV/TV from 6 to 10 months is actually greater 
in WT mice, despite Mfap2−/− mice having a greater accrual of 
MAT. Specifically, in WT mice, BV/TV loss is 32% and MAT 
volume increases 54%; however, MAT volume in Mfap2−/− mice is 
increased 530% but BV/TV is decreased only 22%.
Marrow adipocytes are considered as members of the hemat-
opoietic niche. Marrow adiposity and hematopoiesis have been 
studied in the context of marrow ablation by irradiation and 
chemotherapy. From these studies, it was concluded that the fill-
ing of the marrow with fat impedes marrow reconstitution and 
hematopoiesis (29–31). The current study investigated the conse-
quence of pathologic MAT expansion on existing hematopoietic 
cells (not reconstitution). We found a significant reduction in cir-
culating WBCs and a small increase in spleen cellularity, indicators 
of BM failure and extramedullary hematopoiesis. Further study is 
needed to determine whether MAT expansion in this model leads 
to a loss of functional hematopoietic stem cells. Unexpectedly, 
however, total BM cellularity was unchanged. This may be due 
to shifts in marrow composition to favor loss of fluid space and 
vascular tone with MAT expansion to allow subsequent preserva-
tion of hematopoiesis. We also examined whether fat expansion 
within the marrow would cause a recruitment (or retention) of 
macrophages. Macrophages are recruited to peripheral adipose 
tissue to allow remodeling of adipose tissue during expansion, 
and because of this, obesity is linked to fat inflammation (32). 
Indeed, we found a slight increase in macrophage frequency 
within Mfap2−/− BM. However, the implications of this finding 
are unclear. Future studies are needed to examine the remodeling 
of the MAT adipocyte niche in response to obesity.
The goal of this project was to determine the association 
between pathologic MAT expansion and peripheral indicators 
of metabolic dysfunction without the use of modified diet. We 
also addressed the relationship between MAT expansion and 
bone mass, and the consequence of pathologic MAT expansion 
on hematopoiesis. We found that MAT volume was not linked 
directly to peripheral fat accumulation and, instead, coincided 
with insulin resistance. Furthermore, we found that bone loss 
occurred, regardless of MAT expansion, in Mfap2−/− relative to 
WT at all ages. Lastly, we show that MAT expansion is associated 
with modest alterations in basal hematopoiesis, including a shift 
from granulopoiesis to B lymphopoiesis.
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